Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Johnson & Johnson’s Imbruvica Will Be a Costly Treatment
Johnson & Johnson’s Imbruvica Will Be a Costly Treatment
Johnson & Johnson’s Imbruvica Will Be a Costly Treatment
Submitted by
admin
on November 18, 2013 - 4:36pm
Source:
Wall St Cheat Sheet
News Tags:
JNJ
Imbruvica
mantle cell lymphoma
Pharmacyclics
Headline:
Johnson & Johnson’s Imbruvica Will Be a Costly Treatment
Do Not Allow Advertisers to Use My Personal information
